Molecular targeting in childhood malignancies using nanoparticles

被引：0

作者：

Satake, Noriko ^{[1
]}

Barisone, Gustavo ^{[2
]}

Diaz, Elva ^{[2
]}

Nitin, Nitin ^{[3
]}

Nolta, Jan ^{[4
]}

Lam, Kit ^{[5
]}

机构：

[1] Univ Calif Davis, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA

[2] Univ Calif Davis, Dept Pharm, Sacramento, CA 95817 USA

[3] Univ Calif Davis, Dept Biol & Agr Engn, Sacramento, CA 95817 USA

[4] Univ Calif Davis, Stem Cell Program, Sacramento, CA 95817 USA

[5] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA

来源：

MICRO- AND NANOTECHNOLOGY SENSORS, SYSTEMS, AND APPLICATIONS IV | 2012年 / 8373卷

关键词：

siRNA; nanoparticles; acute lymphoblastic leukemia; leukemia-specific ligand; targeted therapy; PEGYLATED-LIPOSOMAL DOXORUBICIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA INTERFERENCE; THERAPIES;

D O I：

10.1117/12.920917

中图分类号：

TM [电工技术]; TN [电子技术、通信技术];

学科分类号：

0808 ; 0809 ;

摘要：

The goal of our project is to develop a new therapy for childhood malignancies using nanoformulated siRNA targeting Mxd3, a molecule in the Sonic Hedgehog signaling pathway, which we believe is important for cell survival. We plan to use cancer-specific ligands and superparamagnetic iron oxide nanoparticles (SPIO NPs) to carry siRNA. This delivery system will be tested in mouse xenograft models that we developed with primary cancer tissues. Our current focus is acute lymphoblastic leukemia (ALL), the most common cancer in children. We report our progress to date.

引用

页数：6

共 19 条

[1] Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains
Agliano, Alice
Martin-Padura, Ines
Mancuso, Patrizia
Marighetti, Paola
Rabascio, Cristina
Pruneri, Giancarlo
Shultz, Leonard D.
Bertolini, Francesco
[J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (09) : 2222 - 2227
[2] Maximization of Loading and Stability of ssDNA:Iron Oxide Nanoparticle Complexes Formed through Electrostatic Interaction
Berti, Lorenzo
Woldeyesus, Temesgen
Li, Yuanpei
Lam, Kit S.
[J]. LANGMUIR, 2010, 26 (23) : 18293 - 18299
[3] Late effects among survivors of leukemia during childhood and adolescence
Bhatia, S
[J]. BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (01) : 84 - 92
[4] Current prospects for RNA interference-based therapies
Davidson, Beverly L.
McCray, Paul B., Jr.
[J]. NATURE REVIEWS GENETICS, 2011, 12 (05) : 329 - 340
[5] Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, Mark E.
Zuckerman, Jonathan E.
Choi, Chung Hang J.
Seligson, David
Tolcher, Anthony
Alabi, Christopher A.
Yen, Yun
Heidel, Jeremy D.
Ribas, Antoni
[J]. NATURE, 2010, 464 (7291) : 1067 - U140
[6] Targeted therapy in haematological malignancies
Hamilton, Ashley
Gallipoli, Paolo
Nicholson, Emma
Holyoake, Tessa L.
[J]. JOURNAL OF PATHOLOGY, 2010, 220 (04) : 404 - 418
[7] J Kato, EFFICACY CD22 UNPUB
[8] Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
Lee-Sherick, Alisa B.
Linger, Rachel M. A.
Gore, Lia
Keating, Amy K.
Graham, Douglas K.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (04) : 295 - 311
[9] N Satake, MXD3 THERAPEUT UNPUB
[10] N Satake, VALIDATION HUM UNPUB

← 1 2 →